Almirall has reported positive top-line results from its phase 3 ADorable-1 trial, which evaluated lebrikizumab in children ...

Elevara Medicines has dosed the first patient in its phase 2b START-SYNERGY trial, marking a key step in the development of ELV001, an oral CDK4/6 inhibitor being studied for rheumatoid arthritis in ...

The Oxford-based biotechnology company Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon ...

Incyte has received European Commission approval for Zynyz (retifanlimab) in combination with carboplatin and paclitaxel as a ...

HUTCHMED has initiated a global phase 1/2a clinical trial of HMPL‑A580, its second antibody‑targeted therapy conjugate, in ...

Astellas Pharma has announced that the National Institute for Health and Care Excellence has issued Final Draft Guidance recommending fezolinetant 45 mg once daily for treating moderate to severe ...

Chief Executive Officer Sean A MacDonald added: “The successful completion of this Phase I study represents an important step for Kainova Therapeutics, highlighting the strength of our innovative ...

UCB has announced positive topline results from its BE BOLD trial, the first head‑to‑head study in active psoriatic arthritis to demonstrate superiority of one licensed biologic therapy over an IL‑23 ...

Aplagon has dosed the first patient in its phase 2a HEALING clinical trial evaluating APAC, a first‑in‑class treatment for thrombo‑inflammatory diseases, in people with peripheral arterial occlusive ...

The Briefing Room – what next for healthcare communications?

Finally, there are many risks associated with longer stays: infections; blood clots; muscle weakening and pressure sores, to ...

AI is creating a new market where the super employee is king ...